Humulin N Shortage: What Providers and Prescribers Need to Know in 2026

Patients on Humulin N (insulin isophane human, NPH) continue to report difficulty filling their prescriptions at retail pharmacies. While no active FDA national shortage of Humulin N exists as of 2026, clinicians are increasingly fielding calls from patients who cannot locate their insulin. This guide provides a structured clinical framework for managing this reality: understanding supply dynamics, communicating with patients, and deploying therapeutically appropriate alternatives when needed.

Current Humulin N Supply Status (2026)

As of 2026, the FDA Drug Shortages database does not list Humulin N in an active national shortage. Eli Lilly has not issued a shortage notice. However, the 2024 insulin supply disruptions — particularly the temporary out-of-stock of Humalog 10 mL vials and the discontinuation of Humalog 3 mL vials — created systemic instability in insulin distribution networks. The downstream effects include:

Residual patient anxiety about insulin availability, leading to early refills and stockpiling that temporarily depletes local pharmacy inventories

Increased demand from Lilly's Q4 2023 price cuts and $35/month cap, which brought more patients back to full-dose adherence

Uneven distribution across pharmacy networks, with smaller independents more vulnerable to localized stock gaps

Clinical Profile of Humulin N

Humulin N is an intermediate-acting human insulin (NPH) with the following pharmacokinetic profile:

Onset: 1-3 hours

Peak: 4-12 hours

Duration: 12-18 hours

Concentration: 100 units/mL (U-100)

Route: Subcutaneous injection only (NOT for IV or insulin pump use)

Humulin N is FDA-indicated for glycemic control in adults and pediatric patients with Type 1 and Type 2 diabetes mellitus. It may be used as basal insulin or mixed with Humulin R or Humalog (draw NPH last). It is not indicated for IV administration, in insulin pumps, or for treatment of DKA.

Therapeutic Alternatives When Humulin N Is Unavailable

When a patient cannot obtain Humulin N, the following clinically appropriate alternatives should be considered in order of formulary accessibility and patient-specific factors:

1. Novolin N (insulin NPH, Novo Nordisk): Same drug class, same pharmacokinetic profile, OTC available without a prescription, available at Walmart (ReliOn, ~$25/vial). This is the most accessible immediate substitute. Inform patients that while the active ingredient is the same, minor formulation differences exist and blood glucose monitoring should be increased during transition.

2. Insulin glargine (Basaglar, Lantus, Semglee): Long-acting analogs with a flat, peakless 24-hour profile. Generally lower hypoglycemia risk than NPH. When switching from NPH to glargine, the initial glargine dose is typically 80% of the total daily NPH dose (to account for the more potent and flat effect). A once-daily dosing schedule will likely be appropriate. Requires a new prescription.

3. Insulin degludec (Tresiba): Ultra-long-acting (up to 42 hours), once-daily, extremely flat profile. May be appropriate for patients with high hypoglycemia risk or those who struggle with dose timing consistency. Requires dose conversion and prescription.

Key Clinical Cautions When Switching Basal Insulins

Any basal insulin change requires dose recalculation and increased SMBG or CGM monitoring for at least 1-2 weeks

Switching from a peak-containing insulin (NPH) to a peakless analog (glargine/degludec) may require adjustment to the patient's prandial insulin regimen if they are on basal-bolus therapy

Patients switching from NPH twice daily to glargine once daily should be closely monitored for nocturnal hypoglycemia during the first week

Do not switch between glargine products (Lantus vs. Basaglar vs. Semglee) without prescriber approval — they are not all pharmacist-interchangeable

Communicating With Patients About Supply Issues

Proactive communication can prevent emergencies. Consider implementing these office protocols:

Advise all insulin-dependent patients to refill 7-10 days before running out, not when they take their last dose

Remind patients that Humulin N is available OTC — if a pharmacy is out, they can ask the pharmacist for it without a prescription

Document a contingency insulin plan in each patient's chart for shortage situations

Consider sending preemptive refill reminders or MyChart messages to insulin-dependent patients when supply constraints are reported locally

A Tool to Help Your Patients Find Humulin N

When patients call your office saying they cannot find their insulin, directing them to medfinder can reduce the burden on your staff. medfinder calls pharmacies near the patient to identify which ones have their medication in stock. Results are texted to the patient. This is particularly useful when multiple pharmacies need to be checked quickly. For more guidance, see our provider's guide: How to Help Your Patients Find Humulin N in Stock.